Geron Corporation

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Show More...

  • Website https://www.geron.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 1.31 EUR
  • Last Updated 30-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share USD -1.14 -0.78 -0.54 -0.3 -0.23 -0.19 -0.18 -0.15 -0.36 -0.39
    Dividends USD
    Payout Ratio % *
    Shares Mil 98.0 125.0 127.0 128.0 154.0 163.0 159.0 159.0 177.0 190.0 194.0
    Book Value Per Share * EUR 0.95 1.03 0.58 0.34 0.72 0.85 0.77 0.57 0.86 0.68 0.35
    Free Cash Flow Per Share * EUR -0.31 -0.38 -0.39 -0.23 -0.15 0.05 -0.14 -0.09 -0.12 -0.18
    Return on Assets % -53.81 -49.21 -53.02 -45.92 -29.74 0.03 -21.17 -23.21 -18.28 -39.08 -46.99
    Financial Leverage (Average) 1.21 1.09 1.17 1.13 1.32 1.05 1.06 1.06 1.04 1.22 1.18
    Return on Equity % -60.98 -57.08 -59.31 -52.79 -37.45 0.03 -22.33 -24.69 -19.19 -43.82 -51.58
    Return on Invested Capital % -61.67 -57.39 -61.78 -54.02 -37.76 -0.23 -23.17 -25.87 -21.53 -45.77 -52.1
    Interest Coverage -777.21 -382.56 -294.63 -684.34 -434.0 1.52 -354.87 -361.55
    Current Ratio 4.77 9.34 6.96 8.84 3.67 17.47 14.76 14.73 21.99 5.03 7.93
    Quick Ratio 4.61 9.13 6.81 8.67 3.65 17.33 14.65 14.6 21.78 4.98 7.85
    Debt/Equity 0.02 0.04